Patients struggling with withdrawal symptoms may find new relief
Lucemyra (lofexidine hydrochloride), now approved by the Food and Drug Administration, may offer relief (and new hope) for patients experiencing withdrawal symptoms from opioid dependence.
This is the first non-opioid treatment for opioid withdrawal and although it may not completely prevent symptoms, it may lessen the severity (approved for use for up to 14 days). Lucemyra is not a treatment for opioid use disorder (OUD), though it can be used as part of a long-term plan for managing OUD.
In addition, many opioid addicts don’t seek treatment because they fear withdrawal symptoms or relapse easily because of them. A new medication that can ease the process may contribute to recovery rates as a whole.
Read more here on Drugs.com: https://bit.ly/2y2PH8C